We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amicus' (FOLD) Shares Rise on Q3 Earnings & Revenue Beat
Read MoreHide Full Article
Shares of Amicus Therapeutics, Inc. (FOLD - Free Report) grew almost 3.8% since its third-quarter earnings release on Nov 11. However, the stock has declined 3.1% so far this year against the industry’s growth of 1.2%.
Amicus reported a loss of 24 cents per share in the third quarter of 2019, narrower than the Zacks Consensus Estimate of a loss of 32 cents and the year-ago quarter’s loss of 84 cents.
Total revenues in the reported quarter were $48.8 million, skyrocketing almost 137% from $20.6 million in the year-ago quarter. The figure also surpassed the Zacks Consensus Estimate of $48 million. The company realized revenues from the commercial sales of its only marketed drug, Galafold (migalastat).
Sales of Galafold rose 11% from total revenues of $44.1 million in the second quarter of 2019. As of Sep 30, Galafold represented an estimated 30% of the global market share of treated amenable patients.
The company is on track to complete enrollment of 120+ patients in the AT-GAA Pompe pivotal study by the end of 2019.
2019 Guidance
Owing to strength in global Galafold launch metrics across all major geographies, Amicus updated the lower end of 2019 Galafold revenue guidance to $170-$180 million from $160-$180 million.
The company expects to almost double annual worldwide revenues, with more than 1,000 Fabry patients on Galafold, by end of the year.
The company expects to end 2019 with more than $420 million of cash in hand and has extended the cash runway projection from 2021 to the first half of 2022.
Pipeline Update
The lead pipeline candidate in Amicus’ portfolio is AT-GAA, a differentiated biologic for Pompe disease. The company is on track to complete enrollment in the pivotal phase III PROPEL study in Pompe disease and report additional phase II data.
Amicus has two gene-therapy programs for two different types of Batten disease. It expects to report additional two-year results from the phase I/II study in CLN6 Batten disease and complete enrollment in the ongoing CLN3 Batten disease phase I/II study.
Amicus Therapeutics, Inc. Price, Consensus and EPS Surprise
Alkermes’ earnings per share estimates have increased from 36 cents to 52 cents for 2019 in the past 60 days. The company delivered a positive earnings surprise in the trailing four quarters by 236.80% on average.
Anika’s earnings per share estimates have increased from $1.75 to $2.03 for 2019 and from $1.36 to $1.62 for 2020 in the past 60 days. The company delivered a positive earnings surprise in the trailing four quarters by 53.31% on average.
Agenus’ loss per share estimates have narrowed from a loss of $1.04 to 96 cents for 2019 in the past 60 days. The company delivered a positive earnings surprise in two of the trailing four quarters by 23.79% on average.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Amicus' (FOLD) Shares Rise on Q3 Earnings & Revenue Beat
Shares of Amicus Therapeutics, Inc. (FOLD - Free Report) grew almost 3.8% since its third-quarter earnings release on Nov 11. However, the stock has declined 3.1% so far this year against the industry’s growth of 1.2%.
Amicus reported a loss of 24 cents per share in the third quarter of 2019, narrower than the Zacks Consensus Estimate of a loss of 32 cents and the year-ago quarter’s loss of 84 cents.
Total revenues in the reported quarter were $48.8 million, skyrocketing almost 137% from $20.6 million in the year-ago quarter. The figure also surpassed the Zacks Consensus Estimate of $48 million. The company realized revenues from the commercial sales of its only marketed drug, Galafold (migalastat).
Sales of Galafold rose 11% from total revenues of $44.1 million in the second quarter of 2019. As of Sep 30, Galafold represented an estimated 30% of the global market share of treated amenable patients.
The company is on track to complete enrollment of 120+ patients in the AT-GAA Pompe pivotal study by the end of 2019.
2019 Guidance
Owing to strength in global Galafold launch metrics across all major geographies, Amicus updated the lower end of 2019 Galafold revenue guidance to $170-$180 million from $160-$180 million.
The company expects to almost double annual worldwide revenues, with more than 1,000 Fabry patients on Galafold, by end of the year.
The company expects to end 2019 with more than $420 million of cash in hand and has extended the cash runway projection from 2021 to the first half of 2022.
Pipeline Update
The lead pipeline candidate in Amicus’ portfolio is AT-GAA, a differentiated biologic for Pompe disease. The company is on track to complete enrollment in the pivotal phase III PROPEL study in Pompe disease and report additional phase II data.
Amicus has two gene-therapy programs for two different types of Batten disease. It expects to report additional two-year results from the phase I/II study in CLN6 Batten disease and complete enrollment in the ongoing CLN3 Batten disease phase I/II study.
Amicus Therapeutics, Inc. Price, Consensus and EPS Surprise
Amicus Therapeutics, Inc. price-consensus-eps-surprise-chart | Amicus Therapeutics, Inc. Quote
Zacks Rank and Stocks to Consider
Amicus currently carries a Zacks Rank #2 (Buy).
A few top-ranked stocks in the biotech sector are Alkermes Plc. (ALKS - Free Report) , Anika Therapeutics Inc. (ANIK - Free Report) and Agenus Inc. (AGEN - Free Report) , all sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Alkermes’ earnings per share estimates have increased from 36 cents to 52 cents for 2019 in the past 60 days. The company delivered a positive earnings surprise in the trailing four quarters by 236.80% on average.
Anika’s earnings per share estimates have increased from $1.75 to $2.03 for 2019 and from $1.36 to $1.62 for 2020 in the past 60 days. The company delivered a positive earnings surprise in the trailing four quarters by 53.31% on average.
Agenus’ loss per share estimates have narrowed from a loss of $1.04 to 96 cents for 2019 in the past 60 days. The company delivered a positive earnings surprise in two of the trailing four quarters by 23.79% on average.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>